Editas Medicine, Inc. (EDIT) Analysts See $-0.71 EPS

October 13, 2018 - By Michael Collier

Editas Medicine, Inc. (NASDAQ:EDIT) Logo

Analysts expect Editas Medicine, Inc. (NASDAQ:EDIT) to report $-0.71 EPS on November, 6.They anticipate $0.07 EPS change or 10.94 % from last quarter’s $-0.64 EPS. After having $-0.82 EPS previously, Editas Medicine, Inc.’s analysts see -13.41 % EPS growth. The stock increased 2.90% or $0.77 during the last trading session, reaching $27.32. About 567,627 shares traded. Editas Medicine, Inc. (NASDAQ:EDIT) has risen 63.02% since October 14, 2017 and is uptrending. It has outperformed by 47.40% the S&P500.

Editas Medicine, Inc. operates as a genome editing company. The company has market cap of $1.29 billion. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It currently has negative earnings. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

More notable recent Editas Medicine, Inc. (NASDAQ:EDIT) news were published by: Seekingalpha.com which released: “Orchard Rx files for IPO of American shares” on October 04, 2018, also Fool.com with their article: “Better Buy: Crispr Therapeutics AG vs. Editas” published on October 09, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on October 10, 2018. More interesting news about Editas Medicine, Inc. (NASDAQ:EDIT) were released by: Seekingalpha.com and their article: “Long-Term Outlook For Editas Medicine: October 10, 2018” published on October 11, 2018 as well as Globenewswire.com‘s news article titled: “Editas Medicine Grows Scientific Leadership with Two New Appointments” with publication date: October 01, 2018.

Editas Medicine, Inc. (NASDAQ:EDIT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>